(FRX)


NYSE - NYSE Delayed Price. Currency in USD
0.000.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.00
Prev Close0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52wk Range
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
BetaN/A
Volume0
Avg Vol (3m)N/A
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Zackslast year

    Universal Forest Products (UFPI): The Perfect Mix of Value and Rising Earnings Estimates? - Tale of the Tape

    Universal Forest Products is not just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well

  • TheStreet.comlast year

    5 Stocks Ready for Breakouts

    These stocks look ready to break out and trade higher from current levels.

  • Bloomberg2 years ago

    Actavis’s Dealmaking New CEO Has ‘Zero Plans’ for Sale

    Actavis (ACT) Plc is reinventing itself as a diverse pharmaceutical company after growing into of the world’s biggest generic drugmakers. After revitalizing a deeply distressed Bausch & Lomb Inc. and selling it to Valeant Pharmaceuticals International Inc. for $8.7 million in 2013, Brent Saunders moved to Forest Laboratories Inc. (FRX) where, in just five months, he shored up its pipeline and sold the company to Actavis for $21.8 billion. Saunders starts today as Actavis’s chief executive officer and will join the board. “This company is clearly not running any kind of sales process or even contemplating ever running one,” he said in an interview at Actavis’s operational headquarters in Parsippany, New Jersey.